The last time I wrote about Centessa Pharmaceuticals plc (NASDAQ:CNTA), it was in a Seeking Alpha article entitled “Centessa ...

The U.S. Food and Drug Administration has approved the first generic version of Victoza (liraglutide injection), ...

Adenosine deaminase 2 (ADA2) has been identified as a regulator of toll-like receptor 9 (TLR9) activation in response to ...

Novo Nordisk's CagriSema Phase 3 data showed 22.7% weight loss, missing the company's own 25% target, causing a 20% drop in ...

Novo Nordisk’s (NVO) next-gen weight loss therapy, CagriSema, caused up to ~23% of weight loss compared to ~16% of weight ...

"Since our lead drug targets excess pro-inflammatory TNF-alpha, a primary cause of sarcopenia ... GLP-1 agonists are expected to be the top selling drug class in 2024. 2 The GLP-1 agonist market is ...

Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and ...

Researchers at Mount Sinai are developing a revolutionary pill using harmine, a DYRK1A inhibitor, to regenerate ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe e ...

It’s been a minute since Lifehacker looked at the slang of Generation Z—long enough that Generation Alpha has had time to develop and spread some of its own special buzzwords and jargon.

We look forward to sharing for rosnilimab, a depleter and agonist targeting PD-1+ T cells, top-line Phase 2b rheumatoid arthritis data in February 2025 and top-line Phase 2 ulcerative colitis data ...

We look forward to sharing for rosnilimab, a depleter and agonist targeting PD-1+ T cells, top-line Phase 2b rheumatoid arthritis data in February 2025 and top-line Phase 2 ulcerative colitis data in ...